Overview

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen Research (Munich) GmbH
Treatments:
Antibodies, Monoclonal
Fluorouracil
Leucovorin
Oxaliplatin